Comparison of intranasal with targeted lymph node immunization using PR8-Flu ISCOM adjuvanted HIV antigens in macaques

Journal of Medical Virology

Volumn 79, Issue 5, 2007, Pages 474-482

  Koopman, G ^a   Bogers, W M J M ^a   Van Gils, M ^a   Koornstra, W ^a   Barnett, S ^a,b   Morein, B ^c   Lehner, T ^d   Heeney, J L ^a  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b Novartis Vaccines and Diagnostics Inc   (United States)

^c NATIONAL VETERINARY INSTITUTE   (Sweden)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

HIV vaccine; ISCOM; Mucosal

Indexed keywords

CYTOKINE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOLOGICAL ADJUVANT; ISCOM;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG FORMULATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; INTERMETHOD COMPARISON; LYMPHOCYTE PROLIFERATION; MUCOSAL IMMUNITY; NONHUMAN; RHESUS MONKEY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; AIDS VACCINES; ANIMALS; ANTIBODY SPECIFICITY; FEMALE; HIV ANTIBODIES; HIV CORE PROTEIN P24; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN A; INJECTIONS, INTRALYMPHATIC; ISCOMS; MACACA MULATTA; VACCINES, SUBUNIT; VAGINA;

ANIMALIA; MACACA; MACACA MULATTA; MUS; PRIMATES;

EID: 34147160202     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20860     Document Type: Article

References (53)

1. Belyakov IM, Berzofsky JA. 2004. Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity 20:247-253.
2. Belyakov IM, Hel Z, Kelsall B, Kuznetsov VA, Ahlers JD, Nacsa J, Watkins DI, Allen TM, Sette A, Altman J, Woodward R, Markham PD, Clements JD, Franchini G, Strober W, Berzofsky JA. 2001. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med 7:1320-1326.
3. Bogers WM, Bergmeier LA, Ma J, Oostermeijer H, Wang Y, Kelly CG, Ten Haaft P, Singh M, Heeney JL, Lehner T. 2004a. A novel HIV-CCR5 receptor vaccine strategy in the control of mucosal SIV/HIV infection. Aids 18:25-36.
4. Bogers WM, Bergmeier LA, Oostermeijer H, ten Haaft P, Wang Y, Kelly CG, Singh M, Heeney JL, Lehner T. 2004b. CCR5 targeted SIV vaccination strategy preventing or inhibiting SIV infection. Vaccine 22:2974-2984.
5. Brerichley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, Nguyen PL, Khoruts A, Larson M, Haase AT, Douek DC. 2004. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 200:749-759.
6. Cheng-Mayer C, Shioda T, Levy JA. 1991. Host range, replicative, and cytopathic properties of human immunodeficiency virus type 1 are determined by very few amino acid changes in tat and gp!20. J Virol 65:6931-6941.
7. Coulter A, Harris R, Davis R, Drane D, Cox J, Ryan D, Sutton P, Rockman S, Pearse M. 2003. Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine. Vaccine 21:946-949.
8. Egan MA, Chong SY, Hagen M, Megati S, Schadeck EB, Piacente P, Ma BJ, Montefiori DC, Haynes BF, Israel ZR, Eldridge JH, Staats HF. 2004a. A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques. Vaccine 22:3774-3788.
9. Egan MA, Chong SY, Rose NF, Megati S, Lopez KJ, Schadeck EB, Johnson JE, Masood A, Piacente P, Druilhet RE, Barras PW, Hasselschwert DL, Reilly P, Mishkin EM, Montefiori DC, Lewis MG, Clarke DK, Hendry RM, Marx PA, Eldridge JH, Udem SA, Israel ZR, Rose JK. 2004b. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: Comparison of intranasal and intramuscular vaccination routes. AIDS Res Hum Retroviruses 20:989-1004.
10. Evans DT, Chen LM, Gillis J, Lin KC, Harty B, Mazzara GP, Donis RO, Mansfield KG, Lifson JD, Desrosiers RC, Galan JE, Johnson RP. 2003. Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system. J Virol 77:2400-2409.
11. Gallichan WS, Woolstencroft RN, Guarasci T, McCluskie MJ, Davis HL, Rosenthal KL. 2001. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol 166:3451-3457.
12. Gherardi MM, Perez-Jimenez E, Najera JL, Esteban M. 2004. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: Enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule. J Immunol 172:6209-6220.
13. Girard M, Meignier B, Barre-Sinoussi F, Kieny MP, Matthews T, Muchmore E, Nara PL, Wei Q, Rimsky L, Weinhold K, et al. 1995. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J Virol 69:6239-6248.
14. Heeney JL, Teeuwsen VJ, van Gils M, Bogers WM, De GiuliMorghen C, Radaelli A, Barnett S, Morein B, Akerblom L, Wang Y, Lehner T, Davis D. 1998. beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques. Proc Natl Acad Sci USA 95:10803-10808.
15. Holmgren J, Czerkinsky C, Eriksson K, Mharandi A. 2003. Mucosal immunisation and adjuvants: A brief overview of recent advances and challenges. Vaccine 21:889-95.
16. Hu KF, Lovgren-Bengtsson K, Morein B. 2001. Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv Drug Deliv Rev 51:149-159.
17. Jiang JQ, Patrick A, Moss RB, Rosenthal KL. 2005. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides. J Virol 79:393-400.
18. Kang SM, Guo L, Yao Q, Skountzou I, Compans RW. 2004. Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens. J Virol 78:9624-9632.
19. Klavinskis LS, Bergmeier LA, Gao L, Mitchell E, Ward RG, Layton G, Brookes R, Meyers NJ, Lehner T. 1996. Mucosal or targeted lymph node immunization of macaques with a particulate SIVp27 protein elicits virus-specific CTL in the ginito rectal mucosa and draining lymph nodes. J Immunol 157:2521-2527.
20. Klavinskis LS, Barnfield C, Gao L, Parker S. 1999. Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts. J Immunol 162:254-262.
21. Lagranderie M, Balazuc AM, Gicquel B, Gheorghiu M. 1997. Oral immunization with recombinant Mycobacterium bovis BCG simian immunodeficiency virus nef induces local and systemic cytotoxic T-lymphocyte responses in mice. J Virol 71:2303-2309.
22. Lehner T. 2003. Innate and adaptive mucosal immunity in protection against HIV infection. Vaccine 21:868-76.
23. Lehner T, Bergmeier LA, Panagiotidi C, Tao L, Brookes R, Klavinskis LS, Walker P, Walker J, Ward G, Hussain L, AJH G, Adams SE. 1992. Induction of mucosal and systemic immunity to a recombinant simian immunodeficiency viral protein. Science 258:1365-1369.
24. Lehner T, Bergmeier LA, Tao L, Panagiotidi C, Klavinskis LS, Hussain L, Ward RG, Meyers N, Adams SE, AJH G, Brookes R. 1994. Targeted lymph node immunization with simian imunodeficiency virus p27 antigen to elicit genital, rectal, and urinary immune responses in nonhuman primates. J Immunol 153:1858-1868.
25. Lehner T, Wang Y, Cranage M, Bergmeier LA, Mitchell E, Tao L, Hall G, Dennis M, Cook N, Brookes R, Klavinskis L, Jones I, Doyle C, Ward R. 1996. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med 2:767-775.
26. Lehner T, Bergmeier LA, Wang Y, Tao L, Sing M, Spallek R, van der Zee R. 2000. Heat shock proteins generate beta-chemokines which function as innate adjuvants enhancing adaptive immunity. Eur J Immunol 30:594-603.
27. M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, Bilska M, Kothe DL, Salazar-Gonzalez JF, Wei X, Decker JM, Hahn BH, Montefiori DC. 2005a. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79:10108-10125.
28. Q, Duan L, Estes JD, Ma ZM, Rourke T, Wang Y, Reilly C, Carlis J, Miller CJ, Haase AT. 2005b. Peak SIV replication in resting memory CD4(+) T cells depletes gut lamina propria CD4(+) T cells. Nature 434:1148-1152.
29. Luciw PA, Potter SJ, Steimer K, Dina D, Levy JA. 1984. Molecular cloning of AIDS-associated retrovirus. Nature 312:760-763.
30. Makitalo B, Lundholm P, Hinkula J, Nilsson C, Karlen K, Morner A, Sutter G, Erfle V, Heeney JL, Wahren B, Biberfeld G, Thorstensson R. 2004. Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen. J Gen Virol 85:2407-2419.
31. Malkevitch N, Patterson LJ, Aldrich K, Richardson E, Alvord WG, Robert-Guroff M. 2003. A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques. J Immunol 170:4281-4289.
32. Matoba N, Magerus A, Geyer BC, Zhang Y, Muralidharan M, Alfsen A, Arntzen CJ, Bomsel M, Mor TS. 2004. A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs. Proc Natl Acad Sci USA 101:13584-13589.
33. Mattapallil JJ, Douek DC, Hul B, Nishimura Y, Martin M, Roederer M. 2005. Massive infection and loss of memory CD4(+) T cells in multiple tissues during acute SIV infection. Nature 434:1093-1097.
34. McCluskie MJ, Weeratna RD, Krieg AM, Davis HL. 2000. CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine 19:950-957.
35. Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, Boden D, Racz P, Markowitz M. 2004. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 200:761-770.
36. Morein B, Hu KF, Abusugra I. 2004. Current status and potential application of ISCOMs in veterinary medicine. Adv Drug Deliv Rev 56:1367-1382.
37. Mowat AM, Maloy KJ, Donachie AM. 1993. Immune-stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens. Immunology 80:527-534.
38. Osterhaus A, de Vries P, Morein B, Akerblom L, Heeney J. 1992. Comparison of protection afforded by whole virus ISCOM versus MDP adjuvanted formalin-inactivated SIV vaccines from IV cell-free or cell-associated homologous challenge. AIDS Res Hum Retroviruses 8:1507-1510.
39. Patterson LJ, Malkevitch N, Pinczewski J, Venzon D, Lou Y, Peng B, Munch C, Leonard M, Richardson E, Aldrich K, Kalyanaraman VS, Pavlakis GN, Robert-Guroff M. 2003. Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120. J Virol 77:8607-8620.
40. Patterson LJ, Malkevitch N, Venzon D, Pinczewski J, Gomez-Roman VR, Wang L, Kalyanaraman VS, Markham PD, Robey FA, Robert-Guroff M. 2004. Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol 78:2212-2221.
41. Putkonen P, Bjorling E, Akerblom L, Thorstensson R, Lovgren K, Benthin L, Chiodi F, Morein B, Biberfeld G, Norrby E, et al. 1994. Long-standing protection of macaques against cell-free HIV-2 with a HIV-2 iscom vaccine. J Acquir Immune Defic Syndr 7:551-559.
42. Pyle SW, Morein B, Bess JW, Jr., Akerblom L, Nara PL, Nigida SM, Jr., Lerche NW, Robey WG, Fischinger PJ, Arthur LO. 1989. Immune response to immunostimulatory complexes (ISCOMs) prepared from human immunodeficiency virus type 1 (HIV-1) or the HIV-1 external envelope glycoprotein (gp120). Vaccine 7:465-473.
43. Rose NF, Marx PA, Luckay A, Nixon DF, Moretto WJ, Donahoe SM, Montefiori D, Roberts A, Buonocore L, Rose JK. 2001. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106:539-549.
44. Schlienger K, Montefiori DC, Mancini M, Riviere Y, Tiollais P, Michel ML. 1994. Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge. J Virol 68:6578-6588.
45. Sjolander S, Drane D, Davis R, Beezum L, Pearse M, Cox J. 2001. Intranasal immunisation with influenza-ISCOM induces strong mucosal as well as systemic antibody and cytotoxic T-lymphocyte responses. Vaccine 19:4072-4080.
46. Smith RE, Donachie AM, Grdic D, Lycke N, Mowat AM. 1999. Immune-stimulating complexes induce an IL-12-dependent cascade of innate immune responses. J Immunol 162:5536-5546.
47. Stephens DM, Eichberg JW, Haigwood NL, Steimer KS, Davis D, Lachmann PJ. 1992. Antibodies are produced to the variable regions of the external envelope glycoprotein of human immunodeficiency virus type 1 in chimpanzees infected with the virus and baboons immunized with a candidate recombinant vaccine. J Gen Virol 73:1099-1106.
48. Vajdy M, Singh M, Kazzaz J, Soenawan E, Ugozzoli M, Zhou F, Srivastava I, Bin Q, Barnett S, Donnelly J, Luciw P, Adamson L, Montefiori D, O'Hagan DT. 2004. Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations. AIDS Res Hum Retroviruses 20:1269-1281.
49. van der Meide PH, Groenestein RJ, de Labie MC, Heeney J, Pala P, Slaoui M. 1995. Enumeration of lymphokine-secreting cells as a quantitative measure for cellular immune responses in rhesus macaques. J Med Primatol 24:271-281.
50. Verschoor EJ, Mooij P, Oostermeijer H, van der Kolk M, ten Haaft P, Verstrepen B, Sun Y, Morein B, Akerblom L, Fuller DH, Barnett SW, Heeney JL. 1999. Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: Evidence for viral clearance. J Virol 73:3292-3300.
51. Villacres-Eriksson M. 1995. Antigen presentation by naive macrophages, dendritic cells and B cells to primed T lymphocytes and their cytokine production following exposure to immunostimulating complexes. Clin Exp Immunol 102:46-52.
52. Wang Y, Kelly CG, Karttunen JT, Whittall T, Lehner PJ, Duncan L, MacAry P, Younson JS, Singh M, Oehlmann W, Cheng G, Bergmeier L, Lehner T. 2001. CD40 is a cellular receptor mediating mycobacterial heat shock protein 70 stimulation of CC-chemokines. Immunity 15:971-983.
53. Yao Q, Zhang R, Guo L, Li M, Chen C. 2004. Th cell-independent immune responses to chimeric hemagglutinin/simian human immunodeficiency virus-like particles vaccine. J Immunol 173:1951-1958.